AskGene Pharma, Inc.
Clinical trials sponsored by AskGene Pharma, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for stomach cancer: targeted combo therapy enters final trial phase Results expected Dec 2026 (estimated)
- New biologic drug ASKG915 enters human trials for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …
Phase 3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…
Phase 1/2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:04 UTC